Qiagen N.V. (QGEN) announced on January 18 that the company received FDA approval to extend the use of its EGFR test for lung cancer. Qiagen’s therascreen EGFR test is used in conjunction with the targeted therapy GILOTRIF as a first-line treatment for metastatic small cell lung cancer. The FDA approval extends the labeling of the […]
On January 24, McDermott International, Inc. (MDR) announced that it was awarded a new contract with Saudi Aramco. The company reported that this is a large contract for the engineering, procurement, construction, and installation of 13 jackets in the Zuluf, Marjan, Berri, and Abu Safah oil fields off the coast of Saudi Arabia. McDermott expects […]
Fluor Corporation (FLR) announced on January 16 that the company was awarded a new contract with Shell. Under the contract, Fluor is responsible for the engineering, procurement, and fabrication of Shell’s Penguins floating production storage and offloading vessel in the North Sea. The amount of the contract was undisclosed but will be booked as revenue […]
On January 12, Myriad Genetics, Inc. (MYGN) announced that the FDA has approved BRACAnalysis CDx as a companion diagnostic for metastatic breast cancer. Healthcare professionals will be able to use this to identify patients with HER2-negative metastatic breast cancer who have a BRCA mutation and may be candidates for treatment with the PARP inhibitor, Lynparza. […]
Target Corporation (TGT) announced on January 9 that holiday sales were strong-than-expected. Comparable sales grew by 3.4% over the previous year, and stores fulfilled 70% of the company’s digital sales. As a result, Target increased guidance for its annual earnings per share from $4.40-$4.60 to $4.64-$4.74. Sonal caught the news and issued an alert […]
Kohl’s Corporation (KSS) reported on January 8 that November and December sales exceeded the previous year by 6.9%. All lines of business and all regions had improved comparable sales from the previous holiday season. Based on the positive holiday results, the company increased earnings guidance for fiscal 2017 to between $4.10 and $4.20 per diluted […]
Extended Stay America, Inc. and ESH Hospitality, Inc. (STAY) announced on January 2 that the company’s Board of Directors has extended the paired share repurchase program through December 31, 2018. Repurchases can be made at the discretion of the management through open market purchases, private negotiations, or another arrangement. The company reiterated its commitment to […]
The December 2017 scorecard for the signals generated from Sonal can be downloaded here. The results are summarized in this table: Scorecard Total Repurchases M&A Guidance Contracts Clinical Trials Correct – Prev Close to Next Close 61% 61% 73% 100% 50% 59% Correct – Prev Close to Next Session Peak 89% 84% 87% 100% 96% […]
Ritchie Bros. (RBA) announced on December 28 that the company was officially awarded two new contracts with the Defense Logistics Agency (DFA), a part of the U.S. Department of Defense. Under the contracts, Ritchie Bros. will purchase, sell, and manage non-rolling stock surplus assets for both the East and West regions. Non-rolling stock assets include […]
On December 21, La Jolla Pharmaceutical Company (LJPC) announced that the FDA approved its drug, Giapreza (angiotensin II). The drug can be used to increase blood pressure in adult patients suffering from septic shock or other distributive shock. La Jolla expects to have the drug available for patients in March 2018. Sonal detected the event […]
Let us send you a summary of the signals Sonal generates EVERY WEEK… and you can decide if you’re missing anything.